AstraZeneca AB & Anor v KRKA dd Novo Mesto & Anor
The judge was entitled to rely on Medicine Managers' evidence to assess likely market behaviour in the counterfactual scenario, reject actual post-launch market share and comparables as unreliable, and apply a 20% uncertainty discount. The damages awarded reflected a fair and liberal assessment of loss caused by the injunction, consistent with established legal principles.
- Parties
- Appellant/claimant: AstraZeneca AB; Appellant/claimant: AstraZeneca UK Ltd; Respondent/defendant: KRKA dd Novo Mesto; Respondent/defendant: Consilient Health Ltd
- Jurisdiction
- England and Wales
- Judgment Date
- 21 May 2015
- Procedural Posture
- Civil Appeal / Judgment on Appeal
- Outcome
- appeal dismissed
- Legal Topics
- Patent Damages, Interim Injunctions, Cross Undertaking in Damages, Market Entry, Loss of First Mover Advantage
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
AstraZeneca AB
Appellant/claimant
AstraZeneca UK Ltd
Appellant/claimant
KRKA dd Novo Mesto
Respondent/defendant
Consilient Health Ltd
Respondent/defendant
Procedural Posture
Civil Appeal / Judgment on Appeal
Legal Issues
- 1 Assessment of damages under cross-undertaking for interim injunction
- 2 Appropriate methodology for quantifying loss of opportunity to enter pharmaceutical market
- 3 Application of uncertainty discount in damages calculation
Ratio Decidendi
The judge was entitled to rely on Medicine Managers' evidence to assess likely market behaviour in the counterfactual scenario, reject actual post-launch market share and comparables as unreliable, and apply a 20% uncertainty discount. The damages awarded reflected a fair and liberal assessment of loss caused by the injunction, consistent with established legal principles.
Court Disposition
appeal dismissed
Orders
- Judgment of Sales J affirmed
- Damages award to defendants in excess of £27 million upheld
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment